Table 1

Demographics and initial ocular characteristics

BCVA responders (120 eyes)BCVA non-responders (21 eyes)Fundus responders (117 eyes)Fundus non-responders (24 eyes)
Age, mean±SD72.6±10.175.9±5.4*72.9±9.973.6±7.9
Male/female gender, no. eyes (male %)80/40 (66.6)15/6 (71.4)78/39 (66.6)17/7 (70.8)
BCVA, logMAR (mean±SD)0.39±0.440.52±0.350.41±0.450.41±0.33
AMD type
 Typical AMD73106419
 PCV34938 5
 RAP13215 0
CRT, mean±SD (μm)404.8±185.7484.2±269.5426.2±209.2361.8±141.0
GLD, mean±SD (μm)3432.1±2207.44007.8±2104.23429.8±2085.13947.0±2675.9
Type 1 CNV, no. eyes (%)74 (61.7)18 (75.0)68 (58.1)22 (91.7)**
Fundus findings, no. eyes (%)
Serous PED50 (41.7)11 (52.4)52 (44.4)9 (37.5)
Fibrovascular PED35 (29.2)11 (52.4)30 (25.7)16 (66.6)**
Haemorrhagic PED11 (9.2)6 (28.6)14 (20.0)3 (4.2)
Serous retinal detachment71 (59.2)13 (61.9)70 (59.8)14 (54.2)
Macular oedema30 (33.3)6 (28.6)33 (28.2)3 (12.5)**
Retinal haemorrhage38 (32.5)7 (33.3)39 (33.3)6 (25.0)
  • *p<0.05, **p<0.01.

  • AMD, age-related macular degeneration; BCVA, best corrected visual acuity; CNV, choroidal neovascularisation; CRT, central retinal thickness; GLD, greatest linear dimension; PCV, polypoidal choroidal vasculopathy; PED, pigment epithelial detachment; RAP, retinal angiomatous proliferation.